Despite its explosive growth over the past three decades, the biopharmaceutical sector still faces numerous obstacles. Increasing portfolio complexity, rising demand volatility, stringent regulatory requirements, rising pricing pressures, and rising technological complexity are just a few of the factors that are putting a significant strain on profit margins. To conquer such tensions, biopharmaceutical activities need to turn out to be more solid and coordinated, and they should acknowledge proficiency acquired in both assembling and supply chains.
In the past, biopharma companies were slow to implement cutting-edge digital technologies like cloud computing, artificial intelligence (AI), and the Internet of Things (IoT). However, as the COVID-19 pandemic began, businesses were compelled to make investments in digital innovation a top priority and incorporate it into all aspects of work. Roadmaps for digital transformation that had been in place for years were suddenly implemented in a matter of months, resulting in significant shifts in how businesses operate.
The application of cutting-edge digital technologies that satisfy business requirements and generate value for patients, the business, and its partners is a component of digital innovation. This incorporates, yet isn't restricted to, advancements, for example, AI, data lakes, cloud computing, augmented/virtual reality (AR/VR), wearables, digital twins, the IoT, blockchain, and quantum computing.
Research showed that, prior to the pandemic, biopharma was behind other industries in digital innovation. Many businesses had not yet placed digital innovation on the same level as other strategic priorities as they did with their incremental approach. However, as soon as the pandemic started, biopharma companies quickly turned to cutting-edge digital technologies to work remotely or virtually.
Computerized change areas of strength offer open doors, including a potential for diminishing 10-20% of regular transformation costs. Biopharmaceutical businesses face many of the same challenges as businesses in other industries, despite the fact that they have access to a wealth of data from biotechnology facilities as well as the resources and ability to invest. When it comes to delivering value and outcomes from its digital journey, the biopharmaceutical industry lags behind other industries like media, retail, and auto manufacturing.
Here are some challenges that biopharmaceutical companies face;
Lack of a cohesive digital transformation strategy and roadmap,
A focus on high-value use cases,
Difficulty for leadership to comprehend technologies and envision their potential impact,
Insufficient investment in digital capability, difficulty piloting experimental technology, and
A lack of regulatory clarity regarding the use of emerging technologies are all contributing factors.
The industry is progressively capturing value from a wide range of data and creating digital ecosystems that can possibly revolutionize patient care. In order to produce effective targeted therapies, manufacturing needs to shrink, speed up, and become more effective. The industry can use digital technology and data science to reengineer key aspects of the drug manufacturing process to increase flexibility, efficiency, confidence, and, most importantly, ease commercial scale-up by working together across industries. The advancement of healthcare and improvement of patient outcomes will depend on the biopharma industry's digitization.
Join us on 28th - 29th March, 2023 for the International Bioprocessing and Biologics Forum, in Berlin, Germany so you don't feel left out in the industry!
To register or learn more about the Forum please check here: https://bit.ly/3zxguXW
For more information and group participation, contact us: [email protected]